A securities class action has been filed in the USDC – N.D.IL. against Baxter International, Inc. (BAX) (“Baxter” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Baxter common stock between February 23, 2022, and July 30, 2025, both dates inclusive (the “Class Period”).
Baxter is a global, diversified healthcare company that develops, manufactures, and markets a variety of healthcare products used by hospitals, clinics, dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients in their homes. Baxter’s operations are made up of three segments: Medical Products & Therapies (“MPT”), Healthcare Systems & Technologies, and Pharmaceuticals. The MPT segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products.
The Complaint alleges that throughout the Class Period, Defendants misled investors by failing to disclose that:
(1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death;
(2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects;
(3) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients;
(4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and
(5) based on the foregoing, Baxter’s statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading, thereby harming investors.
Baxter stock dropped 22.4 percent, closing at $21.76 on July 31, 2025.
If you purchased Baxter common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.